Welcome to our dedicated page for Wesco Intl SEC filings (Ticker: WCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating how WESCO International’s three operating segments—Electrical & Electronic, Communications & Security, Utility & Broadband—each affect working capital inside a 300-page filing can feel like searching for circuit diagrams in the dark. Investors often ask, “How do I read WESCO International’s 10-K?� or “Where are WESCO International insider trading Form 4 transactions listed?� The complexity of global distribution contracts, inventory turns, and acquisition disclosures makes even seasoned analysts hesitate.
Stock Titan solves this problem by pairing every newly posted document on EDGAR with AI-powered summaries. Want a "WESCO International quarterly earnings report 10-Q filing" without decoding footnotes? We highlight segment revenue shifts, backlog changes, and cash-flow swings in plain English. Prefer bullet-speed alerts on "WESCO International Form 4 insider transactions real-time"? Our dashboard notifies you the moment executives trade shares. Each page delivers "WESCO International SEC filings explained simply", whether you open a 10-K, 10-Q, 8-K, Form 4, S-8, or the "WESCO International proxy statement executive compensation" package.
Use the platform for deep "WESCO International earnings report filing analysis", compare backlog trends quarter over quarter, or export tables for your model. If you’re "understanding WESCO International SEC documents with AI" for the first time, start with the "WESCO International annual report 10-K simplified" section; it condenses risk factors, supplier concentration, and inventory exposure into a five-minute read. Planning to track leadership incentives? The "WESCO International executive stock transactions Form 4" view ties each trade to job title and vesting schedule. Material acquisitions or supply chain disruptions appear in our "WESCO International 8-K material events explained" panel, updated in seconds. AGÕæÈ˹ٷ½-time data, expert context, and one click access—everything you need in a single, focused hub.
IGM Biosciences, Inc. (IGMS) � Form 4 filing dated 07/02/2025
Baker Bros. Advisors LP and affiliated investment funds (667, L.P. and Baker Brothers Life Sciences, L.P.) reported the receipt of 953 fully-vested restricted stock units (RSUs) on 06/30/2025. The RSUs were issued to Felix J. Baker in lieu of a $11,500 board retainer under the company’s Outside Director Compensation Policy. No cash was paid for the shares (price reported as $0).
Post-transaction indirect beneficial ownership stands at
- 357,048 common shares held for the benefit of 667, L.P.
- 3,763,362 common shares held for the benefit of Baker Brothers Life Sciences, L.P.
The filing is administrative in nature—reflecting routine director compensation rather than open-market buying or selling—and does not alter the group’s sizable strategic stake in the company.
LightWave Acquisition Corp. (Nasdaq: LWACU) filed an 8-K to report the successful completion of its initial public offering and related private placement. On 26 June 2025 the blank-check company issued 21,562,500 units at $10.00 each, including the full exercise of the underwriter’s 2,812,500-unit over-allotment option, producing $215.625 million of gross proceeds. Each unit contains one Class A ordinary share and one-half of a redeemable warrant exercisable at $11.50 per share.
Concurrently, the sponsor and BTIG, LLC purchased 606,250 private-placement units (390,625 and 215,625 units, respectively) at the same $10.00 price, generating an additional $6.062 million. No underwriting discount was paid on these units, which were issued under the Section 4(a)(2) exemption.
Total cash of $215.625 million—comprised of IPO net proceeds (after including $7.547 million of deferred underwriting discount) and private-placement proceeds—was deposited into a U.S. trust account at Continental Stock Transfer & Trust. The funds will be held until LightWave completes a business combination, consistent with standard SPAC practice.
An audited balance sheet dated 26 June 2025 reflecting these transactions is attached as Exhibit 99.1. No other material events were disclosed.
Form 4 filing for WESCO International Inc. (WCC) reports that Executive Vice President of Supply Chain & Operations, Hemant Porwal, acquired 5.8071 shares of common stock on 06/30/2025. The acquisition results from dividend equivalent rights (DERs) accruing on existing restricted stock units (RSUs); no cash was exchanged (price reported as $0). After the transaction, Porwal beneficially owns 20,529.7168 shares, held directly.
The DERs vest on the same schedule as the underlying RSU award and are economically equivalent to common shares. No derivative securities were bought or sold, and there were no dispositions. Given the very small share amount and routine nature of DER accruals, the filing is administrative and unlikely to materially affect WCC’s valuation or trading dynamics.
Post Holdings, Inc. (POST) � Form 4 filing dated 07/02/2025
Director William P. Stiritz reported an automatic acquisition of 101.906 Post Holdings stock equivalents on 06/30/2025 under the company’s Deferred Compensation Plan for Non-Management Directors. The units were credited at a reference price of $109.03 per share and bring Stiritz’s total holdings to 180,157.157 stock equivalents. These units are settled in cash, one-for-one with Post common stock value, when the director leaves the Board and carry no fixed exercise or expiration dates.
The filing indicates that Stiritz remains a non-management director and the transaction was coded “A,� reflecting an acquisition rather than a sale. No common shares were sold, and there were no changes to direct or indirect ownership structure beyond the additional units credited.
Post Holdings, Inc. (POST) � Form 4 filing dated 07/02/2025
Director William P. Stiritz reported an automatic acquisition of 101.906 Post Holdings stock equivalents on 06/30/2025 under the company’s Deferred Compensation Plan for Non-Management Directors. The units were credited at a reference price of $109.03 per share and bring Stiritz’s total holdings to 180,157.157 stock equivalents. These units are settled in cash, one-for-one with Post common stock value, when the director leaves the Board and carry no fixed exercise or expiration dates.
The filing indicates that Stiritz remains a non-management director and the transaction was coded “A,� reflecting an acquisition rather than a sale. No common shares were sold, and there were no changes to direct or indirect ownership structure beyond the additional units credited.
AG Mortgage Investment Trust, Inc. (MITT) � Form 4 Insider Transaction
Director Debra Ann Hess reported receiving 3,613 shares of common stock on 07/01/2025 under the company’s independent-director compensation policy. The shares are fully vested but may not be sold or transferred while she serves on the board. After this grant, Hess now beneficially owns 79,476 MITT shares, held directly. The transaction price is recorded as $0, reflecting a non-cash equity award rather than an open-market purchase.
AG Mortgage Investment Trust, Inc. (MITT) � Form 4 Insider Transaction
Director Debra Ann Hess reported receiving 3,613 shares of common stock on 07/01/2025 under the company’s independent-director compensation policy. The shares are fully vested but may not be sold or transferred while she serves on the board. After this grant, Hess now beneficially owns 79,476 MITT shares, held directly. The transaction price is recorded as $0, reflecting a non-cash equity award rather than an open-market purchase.
Form 4 insider activity � ClearPoint Neuro, Inc. (CLPT)
Chief Business Officer Jeremy L. Stigall purchased 1,608 shares of ClearPoint Neuro common stock on 06/30/2025 through the company’s Employee Stock Purchase Plan (ESPP). The acquisition price was $10.15, reflecting the ESPP’s 15 % discount to the lower of the market prices on the first or last day of the six-month purchase period (01/01/2025-06/30/2025). After the transaction, Stigall directly owns 72,355 CLPT shares.
No shares were sold and no derivative securities were involved. While the purchase is modest in size, insider buying—especially by a senior officer—tends to be interpreted as a sign of management’s confidence in the company’s prospects, albeit with limited immediate financial impact.
Form 4 insider activity � ClearPoint Neuro, Inc. (CLPT)
Chief Business Officer Jeremy L. Stigall purchased 1,608 shares of ClearPoint Neuro common stock on 06/30/2025 through the company’s Employee Stock Purchase Plan (ESPP). The acquisition price was $10.15, reflecting the ESPP’s 15 % discount to the lower of the market prices on the first or last day of the six-month purchase period (01/01/2025-06/30/2025). After the transaction, Stigall directly owns 72,355 CLPT shares.
No shares were sold and no derivative securities were involved. While the purchase is modest in size, insider buying—especially by a senior officer—tends to be interpreted as a sign of management’s confidence in the company’s prospects, albeit with limited immediate financial impact.
Hillenbrand, Inc. (HI) filed a Form 4 indicating that director Neil S. Novich received a total of 731 Restricted Stock Units (RSUs) on 30 June 2025. The RSUs were granted through the company’s deferred stock award program and conversion of deferred director fees, each carrying dividend-equivalent rights and issued at $0 cost. Depending on grant date, the RSUs either vest immediately or on the earlier of the next annual meeting or one year after grant, with share delivery deferred until Mr. Novich leaves the board or upon specific triggering events such as a change in control. No common-stock purchases or sales were reported, so cash flow and share count remain unaffected. Post-grant, the director’s beneficial holdings across award pools range between roughly 2,800 and 6,000 units, underscoring ongoing equity alignment with shareholders.